CX
Cemex SAB de CV
$12.32
▲ 0.2%Updated Today 12:11 PM ET
CX at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 32/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 69.8% over the last 12 months
Market Cap
$19.65B
P/E
41.14x
Forward P/E (est.)
58.78x
ROE
3.4%
Revenue Growth
3.3%
EPS Growth
-72.7%
Profit Margin
2.7%
FCF Yield
15.9%
Debt / Equity
0.51x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
32/100
Cemex SAB de CV (CX) is a large-cap company in the Construction industry, part of the Industrials sector of the S&P 500, with a market value around $19.65B.
Our model rates CX Weak (32/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CX trades near $12.32, around its 50-day average ($12.61) and 200-day average ($11.44). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 36 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. CX's is $0.36 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CX found buyers near $11.65 (support) and sellers near $13.40 (resistance); its 52-week range is $7.12–$13.67. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Where CX sits versus its Industrials sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 87 Industrials companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How CX stacks up against its Industrials peers — valuation, profitability, and growth versus the sector median.
In the Industrials sector (165 S&P 500 companies), CX ranks #77 of 165 by our overall rating. It trades at a premium versus the sector on earnings (41.1x P/E vs. 32x median) with a lower return on equity (3.4% vs. 19.7%) and slower revenue growth (3.3% vs. 5.2%).
P/E vs sector
41.1x
median 32x
ROE vs sector
3.4%
median 19.7%
Growth vs sector
3.3%
median 5.2%
Sector rank
#77
of 165 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Industrials companies by sub-industry and size. Sector median is across all 165 S&P 500 names in the sector. Educational, not a recommendation.
The case for CX:
- Healthy free-cash-flow yield (~15.9%) funds buybacks and dividends.
- As an established S&P 500 member in Industrials, it brings scale and a long operating history.
The case against CX:
- Thin net margins (2.7%) leave little room for error.
- A rich 41.1x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (32/100).
Valuation risk — at 41.1x earnings, disappointing results could compress the multiple.
Margin risk — thin profitability (2.7%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Cemex SAB de CV is a large-cap industrials business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 41.1x earnings, which our model scores Weak (32/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
CX — frequently asked questions
Is CX a good stock to buy?
We don't give buy or sell advice. Our model rates Cemex SAB de CV Weak (32/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is CX's rating on The Stocks School?
Cemex SAB de CV currently scores 32/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does CX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Cemex SAB de CV's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for CX calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this CX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell CX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.